Here are three quick notes:
1. Firms covering the shares have a one-year price target of $87.88.
2. On Dec. 1, 2016, Robert Baird rated the shares a “buy.”
3. During the second quarter last year, LS Investment Advisors increased its position in AmSurg by 68.7 percent.
More articles on surgery centers:
5 statistics on ENT net revenue per case in ASCs
Mount Sinai establishes Eye and Vision Research Institute: 4 key notes
Nobilis Health Corp. to acquire Hamilton Vein Center for $13.3M — 4 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
